Herceptin breast cancer drug

Herceptin breast cancer drug

A617/0140 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 33.0MB

Downloadable file size: 1.3MB

Price image Pricing

Please login to use the price calculator


Caption: Herceptin breast cancer drug, molecular model. Herceptin (trastuzumab) is a monoclonal antibody comprising two protein chains (blue and pink). It works by binding to and blocking the HER2 receptor, which is found on some breast cancer cells. HER2 (human epidermal growth factor receptor 2) overabundance makes cancer cells faster-growing and more likely to spread. Herceptin treatment greatly improves the chances of curing the cancer. Around 20% of breast cancers have HER2 over-expression, and are thus viable targets for the drug. In the UK in 2005, it was announced that all women with early breast cancer would be tested to see if their tumours would be receptive to Herceptin therapy.

Release details: Model release not required. Property release not required.

Keywords: 21st century, biochemical, biochemistry, biological, biology, breast cancer, cancer drug, cancer treatment, chain, chains, chemical, chemistry, compound, compounds, drug, herceptin, medical, medicine, molecular, molecular model, molecule, monoclonal antibody, oncology, pharmacological, pharmacology, protein, proteins, trastuzumab

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.